

1 **The effects of inhaled corticosteroids on healthy airways**

2 ¹Emanuele Marchi, PhD*, ¹Timothy S.C. Hinks, FRCP, PhD*, ²Matthew Richardson, PhD,
3 ²Latifa Khalfaoui[§], PhD, ²Fiona A. Symon PhD, ³Poojitha Rajasekar, BSc, ³Rachel Clifford,
4 PhD, ²Beverley Hargadon RGN, ⁴Cary D. Austin MD, PhD, ⁵Julia L. MacIsaac, PhD, ⁵Michael
5 S. Kobor, PhD, ²Salman Siddiqui[§], FRCP, ⁴Jordan S. Mar, PhD, ⁴Joseph R. Arron MD, PhD,
6 ⁴David Choy BSc, ²Peter Bradding FRCP, DM.

7 ¹NIHR Oxford Respiratory BRC and Respiratory Medicine Unit, Experimental Medicine,
8 Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK.

9 ²Department of Respiratory Sciences, University of Leicester, Leicester Respiratory NIHR
10 BRC, Glenfield Hospital, Leicester, UK.

11 ³Centre for Respiratory Research, Translational Medical Sciences, School of Medicine;
12 Nottingham NIHR Biomedical Research Centre; and Biodiscovery Institute, University Park,
13 University of Nottingham, Nottingham, UK.

14 ⁴Genentech, Inc. South San Francisco, CA, USA.

15 ⁵Edwin S.H. Leong Centre for Healthy Aging, Department of Medical Genetics, University
16 of British Columbia, Vancouver, Canada.

17 *These authors contributed equally to this manuscript.

18

19 **Corresponding author**

20 Professor Peter Bradding, Department of Respiratory Sciences, University of Leicester,
21 Glenfield Hospital, Leicester, LE3 9QP, UK. Tel: +44 116 258 3998

22 E-mail: pb46@le.ac.uk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 **Running title:** The effects of ICS on healthy airways

24 **Funding sources:** This work was supported by an investigator-led grant from Genentech to
25 the University Hospitals of Leicester NHS Trust, and supported in part by the National Institute
26 for Health Research (NIHR) Leicester Biomedical Research Centre (Respiratory). EM is
27 supported by Asthma+Lung UK (WADR22\100015). TSCH is supported by a Wellcome Trust
28 Fellowship (211050/Z/18/z). RLC is supported by a University of Nottingham Anne McLaren
29 Fellowship. All authors had full access to the data in the study and accept responsibility to
30 submit for publication. The views expressed are those of the authors and not necessarily those
31 of the NHS, the NIHR or the Department of Health.

32

33 **Author contributions**

34 All authors reviewed the data and contributed to its interpretation, edited the manuscript, and
35 approved the final submitted version.

36 Specific contributions:

37 **EM:** Analysed the RNA seq data and drafted the manuscript

38 **TSCH:** Contributed to data analysis and interpretation, and drafting of the manuscript.

39 **MR:** Analysed the RNA seq data.

40 **LC and FAS:** Performed immunohistochemistry, and quantified and collated the data.

41 **PR:** performed and analysed DNA methylation studies

42 **RLC:** Designed, supervised and analysed DNA methylation studies.

43 **BH:** Managed the study, contributed to patient recruitment, collated the demographic data.

44 **CDA:** Contributed to bronchoscopy protocol design.

45 **JLM** and **MSK** performed DNA methylation studies.

46 **SS**: Analysed the RNA seq data.

47 **JRA**: Conceived and designed the study.

48 **DC**: Conceived and designed the study, analysed RNA seq data, drafted the manuscript.

49 **PB**: Conceived and designed the study, wrote the study protocol and ethical application,
50 analysed the data, drafted the manuscript, performed all bronchoscopies. Chief investigator.

51

52 § Current addresses:

53 Latifa Khalfaoui - Mayo Clinic, Rochester, Minnesota, USA

54 Salman Siddiqui - National Heart and Lung Institute, Imperial College, London, UK

55

56 **DESCRIPTOR**: 3.32 Airway gene expression

57

58 This article has an online supplement

59

60 **Word Count: 3493**

61

62 **ABSTRACT**

63 **Rationale:** The effects of inhaled corticosteroids (ICS) on healthy airways are poorly defined.

64 **Objectives:** To delineate the effects of ICS on gene expression in healthy airways, without
65 confounding caused by changes in disease-related genes and disease-related alterations in ICS-
66 responsiveness.

67 **Methods:** Randomised open-label bronchoscopy study of high dose ICS therapy in 30 healthy
68 adult volunteers randomised 2:1 to i) fluticasone propionate 500 mcg bd or ii) no treatment, for
69 4 weeks. Laboratory staff were blinded to allocation. Biopsies and brushings were analysed by
70 immunohistochemistry, bulk RNA sequencing, DNA methylation array and metagenomics.

71 **Measurements and main results:** ICS induced small between-group differences in blood and
72 lamina propria eosinophil numbers, but not in other immunopathological features, blood
73 neutrophils, FeNO, FEV₁, microbiome or DNA methylation. ICS treatment upregulated 72
74 genes in brushings and 53 genes in biopsies, and downregulated 82 genes in brushings and 416
75 genes in biopsies. The most downregulated genes in both tissues were canonical markers of
76 type-2 inflammation (FCER1A, CPA3, IL33, CLEC10A, SERPINB10 and CCR5), T cell-
77 mediated adaptive immunity (TARP, TRBC1, TRBC2, PTPN22, TRAC, CD2, CD8A, HLA-
78 DQB2, CD96, PTPN7), B cell immunity (CD20, immunoglobulin heavy and light chains), and
79 innate immunity, including CD48, Hobit, RANTES, Langerin and GFII1. An IL-17-dependent
80 gene signature was not upregulated by ICS.

81 **Conclusions:** In healthy airways, 4-week ICS exposure reduces gene expression related to both
82 innate and adaptive immunity, and reduces markers of type-2 inflammation. This implies that
83 homeostasis in health involves tonic type-2 signalling in the airway mucosa, which is
84 exquisitely sensitive to ICS.

85 **Abstract word count:** 249

86

87 **Key Words** asthma, health, bronchial biopsy, transcriptome, epigenetics

88

89 **Abbreviations**

90 ASM - airway smooth muscle

91 FeNO – fraction of exhaled nitric oxide

92 FEV₁ - forced expiratory volume

93 ICS - inhaled corticosteroid

94 IQR -interquartile range

95 MBP - major basic protein

96 MC_T – tryptase only mast cell

97 MC_{TC} – tryptase and chymase mast cell

98 PG - prostaglandin

99 RBM - reticular basement membrane

100 RTU – ready-to-use

101 SD - standard deviation

102 T2 – Type-2 cytokines (IL-4, IL-5, IL-13)

103 INTRODUCTION

104 Inhaled corticosteroids (ICS) are the cornerstone of asthma treatment. They attenuate
105 eosinophilic airway inflammation(1,2), improve lung function, and reduce asthma symptoms,
106 exacerbations, and mortality(3). However, their use is also associated with an increased risk of
107 pneumonia(4). Corticosteroids modulate the expression of many molecular pathways at the
108 level of gene transcription, through direct upregulation of anti-inflammatory molecules and β -
109 adrenoceptors (transactivation), and suppression of pro-inflammatory genes, either through
110 direct DNA-binding or via inhibition of pro-inflammatory transcription factor binding
111 (transrepression)(5). In people with severe asthma, ICS are relatively ineffective even at high
112 doses, but the mechanisms behind this corticosteroid insensitivity are poorly understood and
113 likely multi-factorial(6,7).

114 When considering the underlying molecular pathways driving both severe asthma and relative
115 corticosteroid insensitivity, it is unclear to what extent this is driven by pathways that are not
116 responsive to corticosteroids, as opposed to inhibition of corticosteroid signalling. Gene
117 expression profiling in asthmatic epithelial bronchial brushings and bronchial biopsies has
118 identified several molecular pathways present in subgroups of patients with mild, moderate and
119 severe asthma(8,9). Approximately 80% of people with steroid-naïve “mild” asthma
120 demonstrate evidence of blood or airway eosinophilia, with a concomitant increase in the
121 fraction of exhaled nitric oxide (FeNO)(10,11). This phenotype is characterised by increased
122 expression of an airway gene expression signature driven by IL-4 and IL-13(8,9,12,13); tissue
123 eosinophilia is also dependent on IL-5(14). Together these cytokines are described as Th2 or
124 type-2 cytokines (T2). T2 expression and the accompanying eosinophilia are suppressed by
125 ICS in mild asthma(15). In severe asthma, a persistent T2 gene signature is evident in about
126 25% of patients, suggesting corticosteroid insensitivity(8,9). In addition, in severe asthma,

127 about 25% of patients have evidence of an IL-17-dependent gene signature, which is seen only
128 in people on ICS(8,9), and mutually exclusive with the T2 signature. It is therefore not clear
129 whether this IL-17 activity represents an independent corticosteroid-insensitive pathway
130 driving severe asthma or a consequence of ICS therapy. Approximately 50% of people with
131 severe asthma have neither a T2- or IL-17-dependent airway gene signature, and the
132 mechanisms driving their persistent disordered airway physiology remains unknown. So, while
133 gene expression profiling provides insight into the abnormalities present in severe asthmatic
134 airways, the multiple effects of ICS on airway gene expression make it difficult to disentangle
135 the changes due to the disease as opposed to the treatment, and whether corticosteroid activity
136 is inhibited or not.

137 The effects of ICS on healthy airways are poorly defined. We hypothesise that gene expression
138 data in severe asthma will be more interpretable if we can delineate and thus allow for the
139 effects of high dose ICS therapy. We have therefore performed a randomised open label
140 bronchoscopy study of high dose ICS therapy in healthy adult volunteers, with the aim of
141 understanding transcriptional consequences of ICS therapy without the confounding effects
142 due to disease-related processes.

143

144 **METHODS**

145 Detailed methods are provided in the online data supplement.

146 This prospective study was approved by the East Midlands-Leicester Central Research Ethics
147 Committee (reference:15/EM/0313) and registered at clinicaltrials.gov (NCT02476825).
148 Participants gave written informed consent.

149 **Participant population**

150 Healthy volunteers aged 18-65 were eligible, were current non-smokers with <10 pack year
151 smoking history, and had no prior history or clinical evidence of lower respiratory disease with
152 normal spirometry. Participants with a history of rhinitis were required to have a PC₂₀
153 methacholine >16 mg/ml.

154 **Study design**

155 This was a randomised, open-labelled, bronchoscopy study designed to assess the effects of 4
156 weeks treatment with fluticasone propionate on airway gene expression and cellularity in
157 healthy adult volunteers. The primary endpoint was the corticosteroid-inducible gene
158 expression pattern in healthy airways. Secondary endpoints included the relative change from
159 baseline in airway cellularity.

160 30 participants were randomised by a blinded investigator (MR) in a 2:1 ratio to one of two
161 study groups: i) fluticasone propionate 500 mcg b.i.d. via Accuhaler (Diskus) for 4 weeks
162 (n=20), or ii) no treatment (observation) for 4 weeks (n=10). Bronchoscopy was performed at
163 baseline prior to the start of treatment/observation, and at the end of week 4. Genentech and
164 Leicester laboratory support staff were blinded to treatment allocation.

165 To ensure there were sufficient data for analysis, if a subject withdrew before completion of
166 the study, a further subject(s) was randomised after the first 30 randomisations until a total of
167 30 subjects had completed the study.

168 **Bronchoscopy**

169 Subjects underwent bronchoscopy conducted according to British Thoracic Society
170 guidelines(16). Mucosal biopsies and brushes were collected from 2nd-5th generation bronchi
171 under direct vision as per study procedure manual.

172 **Tissue processing, immunohistochemistry and assessment of immunopathology**

173 Please see the online supplement.

174 All pathological data were assessed by an observer blinded to the identity and treatment
175 allocations of the participants.

176 **RNA sequencing**

177 Please see the online supplement.

178 **Bisulphite conversion and DNA methylation arrays, DNA methylation data quality 179 control and normalization, Differential DNA methylation analysis, Expression 180 quantitative trait methylation (eQTM) analysis**

181 Please see the online supplement.

182 **Microbiota Sequence Data Generation, Processing, and Analysis**

183 Please see the online supplement.

184 **Transcriptomic analysis**

185 Sequences in fastq files (in single and pair ends) were aligned using STAR aligner (version
186 2.7.1a) to the human reference genome GRCh38; R package (17)Rsubread was employed for
187 quantification of reads assigned to genes.

188 Raw count pre-processing, normalisation and differential gene expression analysis was
189 performed using R packaged DESeq2, edgeR, and limma. Gene pathways enrichment analysis
190 was executed using R packages fgsea, clusterProfile, and ReactomePA. Heatmaps, volcano and
191 MA plots were generated using in-home R code, ggplot2 and plotly packages(17,18).

192 **Statistical analysis**

193 Basic summary statistical analysis was performed using GraphPad Prism version 7.03
194 (GraphPad Software, San Diego). Parametric and non-parametric data are presented as mean
195 (standard deviation [SD]) and median (interquartile range [IQR]) respectively unless otherwise
196 stated.

197 RESULTS

198 Clinical characteristics

199 We recruited 44 healthy participants. 32 proceeded to bronchoscopy but one patient withdrew
200 from the study after the first bronchoscopy. 31 completed 2 bronchoscopies, but one was
201 subsequently withdrawn due to both <80% medication adherence and an intercurrent
202 asymptomatic bronchitis evident at the 2nd bronchoscopy (with bronchial wash samples
203 positive for a non-Covid coronavirus and Staphylococcus aureus). The clinical characteristics
204 of the 30 participants completing the study are shown in **table 1**.

205 Effects of ICS on biomarker and physiological measurements

206 There was a significant increase in blood eosinophil numbers after 4 weeks in the observation
207 group compared to people using ICS, but this was not related to atopic status (**Supplementary**
208 **figure E1A**). There were no significant between-group differences for changes in blood
209 neutrophils, FeNO or FEV₁ (**Supplementary figure E1B-D**).

210 Effects of ICS on airway inflammatory and structural cells

211 Suitable paired samples for immunohistochemical analysis of the lamina propria were available
212 from 17 participants receiving ICS and 8 undergoing observation (**Figure 1** and
213 **Supplementary Figure E2**). Although there was no significant change in lamina propria
214 eosinophil counts within either group from the 1st to 2nd bronchoscopy, there was a significant
215 between-group difference in the changes ($p=0.01$), due to a non-significant increase in the
216 observation group (**Figure 1A**). There was no correlation between the change in blood
217 eosinophils versus tissue eosinophils in the observation group ($r_s = -0.024$, $p=0.97$). Comparing
218 the changes in measurements from the 1st to 2nd bronchoscopy for the ICS versus the
219 observation group, there were no significant differences between treatment groups for lamina
220 propria neutrophil, tryptase+ or chymase+ mast cell counts, airway smooth muscle (ASM) and

221 epithelial area expressed as a percentage of biopsy area, or reticular basement membrane depth
222 (**Figure 1B-G**)(**Supplementary Figure E2**).

223 **Effects of ICS on airway gene expression**

224 Suitable paired brush and biopsy samples were available for 15 and 20 participants respectively
225 receiving ICS. We observed significant differential expression of genes amongst participants
226 at week 4 compared with baseline in the ICS-treatment group, with upregulation of 72 genes
227 in brushings and 53 genes in biopsies, and downregulation of 82 genes in brushings and 416
228 genes in biopsies (**Figure 2, Supplementary Tables E1-E4, Supplementary Figures E3, E4**).
229 Amongst participants in the observation-only group there were no significant changes in gene
230 expression observed between baseline and week 4 (**Supplementary Figure E5**). There was a
231 close correlation between epithelial brush and bronchial biopsy gene expression, with 20 genes
232 common to the top 24 most significantly differentially upregulated genes in both airway
233 compartments (**Table 2**) and 20 genes common to the top 41 most significantly downregulated
234 genes in both compartments (**Table 3**).

235 The most significantly upregulated genes were predominantly those involved in steroid
236 metabolism (HSD11B2, FKBP5, SULT2B1, SYT8, and SLCO1B3), cellular proliferation
237 (PSCA, TFCEP2L1, IFITM10, ANPEP), cellular metabolism (GRAMD2A, PRODH, GNMT)
238 and cytoskeletal changes (PHACTR3, FAM107A). By contrast genes which were most
239 significantly downregulated in both brushings and biopsies were key components of T2-driven
240 inflammation (FCER1A, CPA3, IL33, CLEC10A, SERPINB10 and CCR5) and T cell-
241 mediated adaptive immunity (TARP, TRBC1, TRBC2, PTPN22, TRAC, CD2, CD8A, HLA-
242 DQB2, CD96, PTPN7) and (**Table 3**). All other top 20 common downregulated genes were
243 involved with innate or adaptive immunity, including the transcription factor Hobit (ZNF683)
244 which promotes lymphocyte tissue residency, the chemokine RANTES (CCL5), the antigen

245 presentation-associated molecule Langerin (CD207), and the growth factor GFI1 which is
246 involved in haematopoiesis, especially of neutrophils. In addition, there was downregulation
247 of genes associated with B cell function and immunoglobulin production (CD20/79, most
248 heavy and variable light chains for IgA, IgG and IgM, JCHAIN), protective innate immunity
249 (e.g. CD48, CD163), mast cell proteases (TPSB1, TPSAB1, CPA3), the beta chain of the high
250 affinity IgE receptor (MS4A2), and prostaglandin D2 synthase (PTGDS1).

251 Consistent with these findings, pathway analysis of bronchial brushings with Reactome showed
252 strong ICS-related downregulation of innate and adaptive pathways, including
253 *'Immunoregulatory interactions between a lymphoid and non-lymphoid cell'*, five pathways
254 related to TCR signaling, the immunological synapse or co-stimulation, with weaker signals
255 for *'Generation of second messenger molecules'*, *'PD-1 signaling'*, and *'Chemokine receptors*
256 *bind chemokines'*, showing the potent ability of ICS to suppress local adaptive T cell immunity
257 (**Supplementary Figures E6, Supplementary Table E5**). Parallel analysis of the bronchial
258 biopsies again showed effects on lymphoid – non-lymphoid interactions and TCR signaling,
259 but also strong suppression of *'Extracellular matrix organization'*, *'Cell surface interactions*
260 *at the vascular wall'* and *'Integrin cell surface interactions'*, suggesting the potential for
261 suppression of inflammatory cell recruitment to the mucosa (**Supplementary Figure E7,**
262 **Supplementary Table E6**). ICS did not upregulate the IL-17-dependent gene signature
263 identified previously in people with moderate-severe asthma (**Supplementary Fig.E8**)

264 Next we compared our set of differentially upregulated genes with a set of 26 genes previously
265 reported as induced by 10 weeks of inhaled fluticasone in bronchial brushings from participants
266 with mild asthma(19). Geneset enrichment analysis profiles showed very close agreement
267 between genesets (**Supplementary Figure E9**), particularly for brushings, which were directly

268 comparable between studies, showing very similar ICS-induced gene induction in health and
269 mild asthma.

270 **Effects of ICS on the airway microbiome**

271 Minimal effects of ICS treatment were observed on the airway microbiome (details in
272 Supplementary Results and **Supplementary Figure E10**).

273 **Effects of ICS on airway DNA methylation**

274 There were minimal effects of ICS treatment on DNA methylation (details in Supplementary
275 Results and **Supplementary Figure E11**).

276

277 **DISCUSSION**

278 In this open label, randomised study in healthy adult volunteers, we have defined genes that
279 are altered directly by medium-term (4 weeks), twice daily high-dose ICS therapy independent
280 of the confounding effect of asthma pathophysiology. Changes in airway cellularity were
281 minimal between ICS treatment and no treatment, and there were no measurable biologically
282 significant effects on the airway microbiome or DNA methylation.

283 By contrast, we observed widespread changes in gene expression following ICS use in
284 these healthy individuals, which predominantly comprised downregulated genes. A striking
285 finding was that the most significantly downregulated genes statistically were canonical
286 markers of T2-driven inflammation. Notably the most highly downregulated gene, in both
287 airway brushes, which predominantly sample the airway epithelium, and mucosal biopsies, was
288 FCER1A which encodes the α chain of the high affinity IgE receptor, a key effector component
289 of mast cell activation by allergens and of T2 immunity, which is highly upregulated in asthma
290 (20,21). In addition, there was downregulation of genes encoding mast cell tryptases (TPSB1,
291 TPSAB1) and carboxypeptidase A3 (CPA3), the beta chain of the high affinity IgE receptor
292 (MS4A2), and prostaglandin D2 synthase (PTGDS1). We did not see a reduction in mast cell
293 numbers in the airway mucosa of these healthy individuals, so the predominant effect of ICS
294 appears to be on gene transcription, rather than mast cell survival, but nevertheless suggests
295 that ICS have a potentially important dampening effect on mast cell function. In biopsies, there
296 was also downregulation of the important mast cell chemoattractants CXCL10 and CXCL11
297 which promote mast cell migration to the ASM in mild steroid-naive asthma through the airway
298 mast cell chemokine receptor CXCR3(22). In people with severe asthma using high dose ICS
299 +/- oral corticosteroids, mast cells are not increased within the ASM (23,24), suggesting
300 suppression of mast cell chemoattractants from ASM may remain corticosteroid-sensitive in

301 severe disease. This is in contrast to the release of mast cell-derived proteases and autacoids
302 which demonstrate ongoing release in severe disease(23,25).

303 Other highly downregulated T2-related genes included IL33, an airway epithelial cell
304 alarmin which acts to promote initiation of T2 responses(26), CLEC10A which is a marker for
305 alternatively activated macrophages(27), SERPINB10 which is highly upregulated on airway
306 epithelium by IL-13 and inhibits Th2 cell apoptosis, and CCR5 whose ligands include CCL5
307 (RANTES), a chemoattractant for eosinophils and mast cells. Moreover PTGS1, which
308 encodes cyclooxygenase-1 was the 7th most downregulated gene in brushings. This enzyme
309 converts arachidonate to prostaglandins and its dysregulation or inhibition is implicated in
310 salicylate-sensitive asthma and sino-nasal eosinophilic inflammation(28). Similarly in
311 biopsies, periostin (POSTN), an IL-13-induced epithelial gene associated with T2 high
312 asthma(29), was also downregulated.

313 Taken together, the ability of ICS to downregulate this extensive set of T2-related genes
314 implies that homeostasis in health involves a low level of tonic T2 signalling in the airway
315 mucosa that is very sensitive to ICS. This would be consistent with the observation that IL-4-
316 and IL-5-positive cells are present in healthy airways(30), as are mast cells and dendritic cells
317 expressing FcεRIα(31). Constitutive T2 signalling is also evident in primary epithelial cell
318 cultures grown at air-liquid interface, where we previously observed that STAT6-dependent
319 genes including POSTN, CLCA1 and SERPINB2 were repressed by NFκB-dependent
320 cytokine stimulation or dexamethasone(32). Thus differentiated bronchial epithelial cells have
321 a low level of tonic STAT6 dependent signalling in the absence of exogenous IL-4 or IL-13.
322 However, FeNO was not reduced by ICS in these healthy volunteers, and NOS2, which
323 regulates FeNO production, was not altered by ICS therapy, suggesting tonic T2 signalling is
324 below the threshold required for pathological FeNO generation.

325 The role of low-level, tonic, constitutive T2 signalling in the airways is uncertain but likely
326 beneficial for tissue homeostasis. T2 immunity exhibits many host-protective functions,
327 including maintaining metabolic homeostasis, suppressing excessive T1 inflammation,
328 maintenance of barrier defence and regulation of tissue regeneration(33-36). For example, IL-
329 33 is pleiotropic and can promote type 2 inflammation but in other contexts it can be
330 immunoregulatory(26), and preserves epithelial integrity during influenza infection in a mouse
331 model(37,38). Thus the effects of type 2 immunity may be context specific and affected by the
332 cellular source and concomitant inflammatory milieu, and at steady state may promote airway
333 epithelial barrier function. Inhibition of homeostatic tonic T2 signalling might therefore have
334 deleterious effects which may have an impact clinically, and might explain an enhanced
335 propensity to proteobacterial colonisation or infection, as was observed in the MEX(39) and
336 RASP-UK(40) studies amongst participants with very low T2 biomarkers.

337 In addition to the inhibition of T2-driven genes, there was marked suppression of molecules
338 involved in both protective innate immunity (e.g. CD48, CEACAM5) and adaptive immunity,
339 with suppression of genes related to dendritic cells (CD207), T cells (e.g. CD2/3/6/8/96,
340 TRBC1/2, TRAC), and B cell function (e.g. CD20/79, most heavy and variable light chains for
341 IgA, IgG and IgM, JCHAIN). This potential impairment of innate, cell-mediated and antibody-
342 dependent immunity likely explains the reproducible dose-dependent increased pneumonia risk
343 in people with asthma and COPD who are using ICS(4). A subgroup of people with asthma
344 also become colonised with certain fungi(41), and it is possible that this is also a consequence
345 of the mucosal immunosuppression observed here.

346 An important aim of this study was to provide information on the activity of ICS in healthy
347 airways, to remove the confounding that might occur due to disease-related changes in gene
348 expression or inherent ICS responsiveness, which should facilitate analyses of gene expression

349 changes in asthma. Studies of severe asthma to-date (42) have attempted to account for the
350 effects of ICS based on gene expression changes derived from in vitro cell cultures, from an
351 interventional study of gene expression changes in people administered ICS for chronic
352 obstructive pulmonary disease, and from one previous intervention study which used
353 microarrays to assess acute airway transcriptional consequences 6 hours after a single inhaled
354 dose of budesonide (1600 µg) in 12 healthy, steroid-naïve men(43). Our findings are
355 complementary to the previous budesonide study in that some differentially regulated genes
356 are common to our two studies (including upregulation of FKBP5, ZBTB16, PHACTR3,
357 TSC22D3 and downregulation of CD207, FCER1A, IL33), but there is a striking difference in
358 the overall consequences of a single dose versus 4 weeks twice daily ICS use. The predominant
359 effect of a single large acute dose of ICS was upregulation of genes (transactivation), with 68
360 genes upregulated and only 28 downregulated. Many of the upregulated genes were
361 proinflammatory including growth factors, chemokines, chemokine receptors, cytokines,
362 growth factors, and coagulation factors. By comparison in our chronic high dose exposure
363 study only 53 genes were upregulated in biopsies, whilst 416 genes were downregulated
364 (transrepression). This highlights the critical and often overlooked importance of the complex
365 temporal dynamics of corticosteroid effects. Early during an acute infectious or traumatic
366 challenge a surge in endogenous corticosteroids will tend to enhance protective inflammatory
367 and procoagulant responses, but as time passes these responses will attenuate and slower but
368 potent transrepressive effects will dominate to curtail uncontrolled inflammatory cell
369 recruitment and activation, to prevent bystander tissue damage, and to direct resolution of tissue
370 homeostasis. It is this latter situation which is of greatest clinical relevance to long term asthma
371 management. Of note, comparing our data to the study by Woodruff(12), where people with
372 mild asthma received inhaled placebo or fluticasone propionate (500 µg) twice daily for 8

373 weeks, there was a strong correlation between the studies for ICS-inducible genes, suggesting
374 that in mild asthma at least, ICS-dependent transactivation is preserved.

375 When considering previous studies of gene expression in severe asthma, an IL-17-
376 dependent gene signature is expressed in a subset of people, and mutually exclusive with a T2
377 gene signature(8,9). This IL-17-dependent signature was only seen in people using ICS, but it
378 has been unclear whether this is disease- or treatment-related, and whether it is harmful or
379 potentially protective. We did not see upregulation of this IL-17 signature after 4 weeks of ICS
380 treatment in this study, thus it seems most likely a feature of disease. Similarly, there is
381 upregulation of CEACAM family members in severe asthma, notably the IL-13-dependent
382 gene CEACAM5(44,45), and CEACAM6 which was increased on both the epithelium and
383 neutrophils in bronchial biopsies(44). Here we found that CEACAM6 expression did not
384 change with ICS treatment, while CEACAM5 expression was reduced (tables E2, E4), in
385 keeping with the inhibition of other T2-related genes. Therefore the upregulation of these
386 CEACAMs in severe asthma appears to be a feature of the disease rather than treatment. In the
387 recent U-BIOPRED bronchoscopy study(24), ICS-inducible genes such as FKBP5 were
388 upregulated in severe asthma, suggesting that their participants were adherent to treatment, and
389 importantly, that ICS transactivation appears to be preserved in severe asthma, but many
390 pathological pathways that should be sensitive to transrepression by ICS such as T2 signalling
391 are not responsive in a subset of patients(8,9,23).

392 There are some limitations to our work. Firstly the effects of ICS in healthy airways at 4
393 weeks, while likely representative of the steady state in long term therapy, might not be fully
394 representative of longer term therapy. However it is not reasonable to ask healthy volunteers
395 to take ICS for a year, and adherence would likely wane. Secondly our analyses use bulk
396 sequencing of airway brushes and biopsies, and ICS effects are likely to be highly cell-specific,

397 so future studies using spatial sequencing, from central and peripheral airways as well as nasal
398 tissues and peripheral blood would be informative. For example, as we did not enumerate all
399 of the cell types implicated in the transcriptomic analyses, we cannot conclude whether the
400 changes in T- and B-lymphocyte related gene expression are due to transcriptional changes
401 within lymphocytes, changes in the relative proportions of lymphocytes in the samples, or a
402 combination of the two.

403 In summary, we defined genes altered directly by ICS therapy without confounding by
404 disease. We provide evidence that IL-17-dependent signalling in asthma is disease-dependent
405 rather than ICS-dependent, and demonstrate downregulation of canonical markers of T2
406 inflammation, implying that homeostasis in health involves tonic T2 signalling in the airway
407 mucosa, which is exquisitely sensitive to ICS. There was also broad suppression of innate and
408 adaptive immunity, in keeping with known immunosuppressive effects of corticosteroids.

409

410 **Acknowledgements**

411 The authors are grateful to all the participants who volunteered and to the clinical and research
412 teams at all the participating centres. For the purpose of Open Access, the author has applied a
413 CC BY public copyright licence to any Author Accepted Manuscript version arising from this
414 submission. The views expressed are those of the authors and not necessarily those of the NHS,
415 the NIHR or the Department of Health and Social Care. The authors vouch for the integrity and
416 completeness of the data and the fidelity of the trial to the protocol. This study has been
417 conducted in accordance with the Declaration of Helsinki and any applicable regulatory
418 requirements.

419 **Data sharing**

420 The data analysed and presented in this study are available from the corresponding author on
421 reasonable request, providing the request meets local ethical and research governance criteria
422 after publication. Patient-level data will be anonymised. The RNA Sequencing data have been
423 deposited in the Gene Expression Omnibus (GEO) under accession number GSE242048.

424

425

426

427 REFERENCES

- 428 1. Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid,
429 budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed
430 asthma: a randomized, double-blind, parallel-group controlled trial. *J Allergy Clin Immunol*
431 1992; 90: 32-42.
- 432 2. Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls, AF, Roche WR, Howarth PH, Holgate ST.
433 Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. *Am Rev*
434 *Respir Dis* 1992; 145: 669-674.
- 435 3. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the
436 prevention of death from asthma. *N Engl J Med* 2000; 343: 332-336.
- 437 4. McKeever T, Harrison TW, Hubbard R, Shaw D. Inhaled corticosteroids and the risk of pneumonia
438 in people with asthma: a case-control study. *Chest* 2013; 144: 1788-1794.
- 439 5. Jaffuel D, Demoly P, Gougat C, Balaguer P, Mautino G, Godard P, Bousquet J, Mathieu M.
440 Transcriptional potencies of inhaled glucocorticoids. *Am J Respir Crit Care Med* 2000; 162:
441 57-63.
- 442 6. Chachi L, Shikotra A, Duffy SM, Tliba O, Brightling C, Bradding P, Amrani Y. Functional KCa3.1
443 channels regulate steroid insensitivity in bronchial smooth muscle cells. *J Immunol* 2013;
444 191: 2624-2636.
- 445 7. Alzahrani A, Hussain A, Alhadian F, Hakeem J, Douaoui S, Tliba O, Bradding P, Amrani Y. Potential
446 Role of Mast Cells in Regulating Corticosteroid Insensitivity in Severe Asthma. *Adv Exp Med*
447 *Biol* 2021; 1303: 1-12.
- 448 8. Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, Siddiqui S, Jia G, Ohri CM, Doran E,
449 Vannella KM, Butler CA, Hargadon B, Sciurba JC, Gieseck RL, Thompson RW, White S, Abbas
450 AR, Jackman J, Wu LC, Egen JG, Heaney LG, Ramalingam TR, Arron JR, Wynn TA, Bradding P.
451 TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. *Sci Transl Med*
452 2015; 7: 301ra129.
- 453 9. Ostling J, van Geest M, Schofield JPR, Jevnikar Z, Wilson S, Ward J, Lutter R, Shaw DE, Bakke PS,
454 Caruso M, Dahlen SE, Fowler SJ, Horvath I, Krug N, Montuschi P, Sanak M, Sandstrom T, Sun
455 K, Pandis I, Auffray C, Sousa AR, Guo Y, Adcock IM, Howarth P, Chung KF, Bigler J, Sterk PJ,
456 Skipp PJ, Djukanovic R, Vaarala O, Group UBS. IL-17-high asthma with features of a psoriasis
457 immunophenotype. *J Allergy Clin Immunol* 2019; 144: 1198-1213.
- 458 10. Berry MA, Morgan A, Shaw DE, Parker D, Green RH, Brightling CE, Bradding P, Wardlaw AJ,
459 Pavord ID. Pathological features and inhaled corticosteroid response of eosinophilic and
460 non-eosinophilic asthma. *Thorax* 2007.
- 461 11. McGrath KW, Icitovic N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM, Fahy JV. A large
462 subgroup of mild-to-moderate asthma is persistently noneosinophilic. *Am J Respir Crit Care*
463 *Med* 2012; 185: 612-619.
- 464 12. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Arron JR, Koth LL, Fahy JV. T-
465 helper type 2-driven inflammation defines major subphenotypes of asthma. *Am J Respir Crit*
466 *Care Med* 2009; 180: 388-395.
- 467 13. Choy DF, Modrek B, Abbas AR, Kummerfeld S, Clark HF, Wu LC, Fedorowicz G, Modrusan Z, Fahy
468 JV, Woodruff PG, Arron JR. Gene Expression Patterns of Th2 Inflammation and Intercellular
469 Communication in Asthmatic Airways. *J Immunol* 2010: doi:10.4049/jimmunol.1002568.
- 470 14. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D,
471 Kay AB. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial
472 subepithelial basement membrane of mild atopic asthmatics. *J Clin Invest* 2003; 112: 1029-
473 1036.

- 474 15. Wallin A, Sandstrom T, Cioppa GD, Holgate S, Wilson S. The effects of regular inhaled formoterol
475 and budesonide on preformed Th-2 cytokines in mild asthmatics. *Respir Med* 2002; 96:
476 1021-1025.
- 477 16. Du Rand IA, Blaikley J, Booton R, Chaudhuri N, Gupta V, Khalid S, Mandal S, Martin J, Mills J,
478 Navani N, Rahman NM, Wrightson JM, Munavvar M. British Thoracic Society guideline for
479 diagnostic flexible bronchoscopy in adults: accredited by NICE. *Thorax* 2013; 68 Suppl 1: i1-
480 i44.
- 481 17. Foundation TR. The R Project for Statistical Computing. [cited 2023 23/05/2023]. Available from:
482 <http://www.r-project.org/index.html>.
- 483 18. Reimers M, Carey VJ. Bioconductor: an open source framework for bioinformatics and
484 computational biology. *Methods Enzymol* 2006; 411: 119-134.
- 485 19. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, Ellwanger A, Sidhu SS,
486 Dao-Pick TP, Pantoja C, Erle DJ, Yamamoto KR, Fahy JV. Genome-wide profiling identifies
487 epithelial cell genes associated with asthma and with treatment response to corticosteroids.
488 *Proc Natl Acad Sci U S A* 2007; 104: 15858-15863.
- 489 20. Singhanian A, Wallington JC, Smith CG, Horowitz D, Staples KJ, Howarth PH, Gadola SD, Djukanovic
490 R, Woelk CH, Hinks TSC. Multitissue Transcriptomics Delineates the Diversity of Airway T Cell
491 Functions in Asthma. *Am J Respir Cell Mol Biol* 2018; 58: 261-270.
- 492 21. Holgate ST. Pathogenesis of asthma. *Clin Exp Allergy* 2008; 38: 872-897.
- 493 22. Brightling CE, Ammit AJ, Kaur D, Black JL, Wardlaw AJ, Hughes JM, Bradding P. The
494 CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth
495 muscle. *Am J Respir Crit Care Med* 2005; 171: 1103-1108.
- 496 23. Khalfaoui L, Symon FA, Couillard S, Hargadon B, Chaudhuri R, Bicknell S, Mansur AH, Shrimanker
497 R, Hinks TSC, Pavord ID, Fowler SJ, Brown V, McGarvey LP, Heaney LG, Austin CD, Howarth
498 PH, Arron JR, Choy DF, Bradding P. Airway remodelling rather than cellular infiltration
499 characterizes both type2 cytokine biomarker-high and -low severe asthma. *Allergy* 2022.
- 500 24. Wilson SJ, Ward JA, Sousa AR, Corfield J, Bansal AT, De Meulder B, Lefaudeux D, Auffray C, Loza
501 MJ, Baribaud F, Fitch N, Sterk PJ, Chung KF, Gibeon D, Sun K, Guo YK, Adcock I, Djukanovic R,
502 Dahlen B, Chanez P, Shaw D, Krug N, Hohlfeld J, Sandstrom T, Howarth PH, Group UBS.
503 Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED
504 study. *Eur Respir J* 2016; 48: 1307-1319.
- 505 25. Hinks TS, Zhou X, Staples KJ, Dimitrov BD, Manta A, Petrossian T, Lum PY, Smith CG, Ward JA,
506 Howarth PH, Walls AF, Gadola SD, Djukanovic R. Innate and adaptive T cells in asthmatic
507 patients: Relationship to severity and disease mechanisms. *J Allergy Clin Immunol* 2015; 136:
508 323-333.
- 509 26. Hung LY, Tanaka Y, Herbine K, Pastore C, Singh B, Ferguson A, Vora N, Douglas B, Zullo K, Behrens
510 EM, Li Hui Tan T, Kohanski MA, Bryce P, Lin C, Kambayashi T, Reed DR, Brown BL, Cohen NA,
511 Herbert DR. Cellular context of IL-33 expression dictates impact on anti-helminth immunity.
512 *Sci Immunol* 2020; 5.
- 513 27. Staples KJ, Hinks TS, Ward JA, Gunn V, Smith C, Djukanovic R. Phenotypic characterization of lung
514 macrophages in asthmatic patients: overexpression of CCL17. *J Allergy Clin Immunol* 2012;
515 130: 1404-1412 e1407.
- 516 28. Pietruszewska W, Fendler W, Podwysocka M, Bialas AJ, Kuna P, Kuprys-Lipinska I, Borowiec M.
517 Expression of Transcript Variants of PTGS1 and PTGS2 Genes among Patients with Chronic
518 Rhinosinusitis with Nasal Polyps. *Diagnostics (Basel)* 2021; 11.
- 519 29. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, Shikotra A, Carter R, Audusseau S,
520 Hamid Q, Bradding P, Fahy JV, Woodruff PG, Harris JM, Arron JR. Periostin is a systemic
521 biomarker of eosinophilic airway inflammation in asthmatic patients. *J Allergy Clin Immunol*
522 2012; 130: 647-654.
- 523 30. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, Heusser CH, Howarth
524 PH, Holgate ST. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and

- 525 asthmatic airways: evidence for the human mast cell as a source of these cytokines. *Am J*
526 *Respir Cell Mol Biol* 1994; 10: 471-480.
- 527 31. Tunon-De-Lara JM, Redington AE, Bradding P, Church MK, Hartley JA, Semper AE, Holgate ST.
528 Dendritic cells in normal and asthmatic airways: expression of the alpha subunit of the high
529 affinity immunoglobulin E receptor (Fc epsilon RI -alpha). *Clin Exp Allergy* 1996; 26: 648-655.
- 530 32. Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, Siddiqui S, Jia G, Ohri CM, Doran E,
531 Vannella KM, Butler CA, Hargadon B, Sciruba JC, Gieseck RL, Thompson RW, White S, Abbas
532 AR, Jackman J, Wu LC, Egen JG, Heaney LG, Ramalingam TR, Arron JR, Wynn TA, Bradding P.
533 TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. *Sci Transl Med*
534 2015; 7: 301ra129.
- 535 33. Gieseck RL, 3rd, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. *Nat Rev*
536 *Immunol* 2018; 18: 62-76.
- 537 34. Van Dyken SJ, Locksley RM. Interleukin-4- and interleukin-13-mediated alternatively activated
538 macrophages: roles in homeostasis and disease. *Annu Rev Immunol* 2013; 31: 317-343.
- 539 35. Goh YP, Henderson NC, Heredia JE, Red Eagle A, Odegaard JI, Lehwald N, Nguyen KD, Sheppard
540 D, Mukundan L, Locksley RM, Chawla A. Eosinophils secrete IL-4 to facilitate liver
541 regeneration. *Proc Natl Acad Sci U S A* 2013; 110: 9914-9919.
- 542 36. Mesnil C, Raulier S, Paulissen G, Xiao X, Birrell MA, Pirottin D, Janss T, Starkl P, Ramery E, Henket
543 M, Schleich FN, Radermecker M, Thielemans K, Gillet L, Thiry M, Belvisi MG, Louis R, Desmet
544 C, Marichal T, Bureau F. Lung-resident eosinophils represent a distinct regulatory eosinophil
545 subset. *J Clin Invest* 2016; 126: 3279-3295.
- 546 37. Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CG, Doering TA, Angelosanto JM,
547 Laidlaw BJ, Yang CY, Sathaliyawala T, Kubota M, Turner D, Diamond JM, Goldrath AW, Farber
548 DL, Collman RG, Wherry EJ, Artis D. Innate lymphoid cells promote lung-tissue homeostasis
549 after infection with influenza virus. *Nat Immunol* 2011; 12: 1045-1054.
- 550 38. Dagher R, Copenhaver AM, Besnard V, Berlin A, Hamidi F, Maret M, Wang J, Qu X, Shrestha Y,
551 Wu J, Gautier G, Raja R, Aubier M, Kolbeck R, Humbles AA, Pretolani M. IL-33-ST2 axis
552 regulates myeloid cell differentiation and activation enabling effective club cell
553 regeneration. *Nature communications* 2020; 11: 4786.
- 554 39. McDowell PJ, Diver S, Yang F, Borg C, Busby J, Brown V, Shrimanker R, Cox C, Brightling CE,
555 Chaudhuri R, Pavord ID, Heaney LG, Medical Research Council: Refractory Asthma
556 Stratification P. The inflammatory profile of exacerbations in patients with severe refractory
557 eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational
558 study. *Lancet Respir Med* 2021; 9: 1174-1184.
- 559 40. Diver S, Haldar K, McDowell PJ, Busby J, Mistry V, Micieli C, Brown V, Cox C, Yang F, Borg C,
560 Shrimanker R, Ramsheh MY, Hardman T, Arron J, Bradding P, Cowan D, Mansur AH, Fowler
561 SJ, Lordan J, Menzies-Gow A, Robinson D, Matthews J, Pavord ID, Chaudhuri R, Heaney LG,
562 Barer MR, Brightling C, Medical Research Council: Refractory Asthma Stratification P.
563 Relationship between inflammatory status and microbial composition in severe asthma and
564 during exacerbation. *Allergy* 2022; 77: 3362-3376.
- 565 41. Agbetile J, Fairs A, Desai D, Hargadon B, Bourne M, Mutalithas K, Edwards R, Morley JP, Monteiro
566 WR, Kulkarni NS, Green RH, Pavord ID, Bradding P, Brightling CE, Wardlaw AJ, Pashley CH.
567 Isolation of filamentous fungi from sputum in asthma is associated with reduced post-
568 bronchodilator FEV1. *Clin Exp Allergy* 2012; 42: 782-791.
- 569 42. Ginebaugh SP, Hagner M, Ray A, Erzurum SC, Comhair SAA, Denlinger LC, Jarjour NN, Castro M,
570 Woodruff PG, Christenson SA, Bleecker ER, Meyers DA, Hastie AT, Moore WC, Mauger DT,
571 Israel E, Levy BD, Wenzel SE, Camiolo MJ. Bronchial epithelial cell transcriptional responses
572 to inhaled corticosteroids dictate severe asthmatic outcomes. *J Allergy Clin Immunol* 2023.
- 573 43. Leigh R, Mostafa MM, King EM, Rider CF, Shah S, Dumonceaux C, Traves SL, McWhae A, Kolisnik
574 T, Kooi C, Slater DM, Kelly MM, Bieda M, Miller-Larsson A, Newton R. An inhaled dose of
575 budesonide induces genes involved in transcription and signaling in the human airways:

- 576 enhancement of anti- and proinflammatory effector genes. *Pharmacol Res Perspect* 2016; 4:
577 e00243.
- 578 44. Shikotra A, Choy DF, Siddiqui S, Arthur G, Nagarkar DR, Jia G, Wright AK, Ohri CM, Doran E, Butler
579 CA, Hargadon B, Abbas AR, Jackman J, Wu LC, Heaney LG, Arron JR, Bradding P. A CEACAM6-
580 High Airway Neutrophil Phenotype and CEACAM6-High Epithelial Cells Are Features of
581 Severe Asthma. *J Immunol* 2017; 198: 3307-3317.
- 582 45. Mumby S, Kermani NZ, Garnett JP, Pavlidis S, Wilson SJ, Howarth PJ, Thomas MJ, Adcock IM,
583 Lopez-Garcia C. CEACAM5 is an IL-13-regulated epithelial gene that mediates transcription in
584 type-2 (T2) high severe asthma. *Allergy* 2022; 77: 3463-3466.

585

586

587 **TABLES**

588 **Table 1 – Demographics of the study participants**

	Healthy – ICS (n=20)	Healthy – observation (n=10)	p value†
Age - years	38 (22-52)	24 (22-33)	0.2
Sex - M/F	8/12	7/3	0.2
BMI (kg/m ²)	24.7 ± 3.7	24.4 ± 2.7	0.8
Ethnicity Caucasian (%)	80	70	0.7
Atopic (%)	25	50	0.2
Ex smoker (%)	20	10	0.6
Smoking (pack years)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.4
FEV ₁ Pre BD (L)	3.32 ± 0.79	4.0 ± 0.93	0.047
FEV ₁ Pre BD (% predicted)	103 ± 11	100 ± 8	0.5
FEV ₁ /FVC (%)	82.1 ± 4.6	82.4 ± 3.3	0.9
FeNO (ppb)	16 (11-25)	18 (15-29)	0.4

Blood eosinophils at

screening ($\times 10^9/L$)	0.11 (0.06-0.15)	0.11 (0.08-0.15)	0.8
-------------------------------	------------------	------------------	-----

589

590 Continuous variables are presented as mean \pm SD or median (interquartile range). BD,

591 bronchodilator; BMI, body mass index; FVC, forced vital capacity; FeNO, fractional exhaled

592 nitric oxide; FEV₁, forced expiratory volume in 1 second; ICS, inhaled corticosteroids.

593 †All tests for continuous variables are t-test or Mann Whitney U. For categorical variables, a

594 Fischer's exact test was used.

595 *P<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

596 **Table 2 – Top upregulated differentially expressed genes**

Gene	Bronchial brushes			Bronchial biopsies			Mean of FDR P values	Comments and aliases	Functional role
	Baseline read count	Log2 fold change	FDR P value	Baseline read count	Log2 fold change	FDR P value			
PHACTR3	497	3.59	1.43E-41	325	3.28	4.29E-38	2.14E-38	Phosphatase And Actin Regulator 3; associated with the nuclear scaffold in proliferating cells.	Cytoskeletal changes
HSD11B2	468	1.89	3.22E-41	392	1.81	9.88E-37	4.94E-37	Hydroxysteroid 11-β Dehydrogenase 2: converts cortisol to cortisone, prevents mineralocorticoid receptor activation	Steroid metabolism
FKBP5	3336	1.88	2.17E-27	5029	1.67	3.14E-20	1.57E-20	Regulates corticosteroid sensitivity; asthma susceptibility gene.	Steroid metabolism
FAM107A	3486	1.45	6.14E-22	3657	1.60	4.02E-17	2.01E-17	Family With Sequence Similarity 107 Member A; role in actin and microtubule organisation.	Cytoskeletal changes
HIF3A	584	3.18	4.42E-17	990	2.67	5.35E-21	2.21E-17	Hypoxia Inducible Factor 3 Subunit α; canonical sensor of hypoxia.	Hypoxic sensing
MYLK3	476	1.10	1.19E-40	490	1.47	6.54E-17	3.27E-17	Myosin Light Chain Kinase 3; Immune response to CCR3 signaling in eosinophils, regulates smooth muscle contracti	Smooth muscle/immune
GP2	341	2.48	1.26E-15	286	3.12	9.81E-28	6.29E-16	Glycoprotein 2; binds pathogens such as enterobacteria.	Innate immune
SULT2B1	1706	1.38	3.05E-17	1199	1.44	2.01E-15	1.02E-15	Hydroxysteroid Sulfotransferase 2; catalyses the sulfate conjugation hormones.	Steroid metabolism
GRAMD2A	2452	1.15	5.37E-24	2309	1.38	2.69E-15	1.35E-15	GRAM Domain Containing 2A; organization of endoplasmic reticulum-plasma membrane contact sites.	Cellular metabolism
SYT8	503	1.12	2.93E-15	470	1.13	2.37E-22	1.46E-15	Synaptotagmin 8; regulate exocytosis of hormones and in intracellular organelles.	Steroid metabolism
SLCO1B3	124	1.94	1.69E-17	111	2.27	5.11E-14	2.55E-14	Solute Carrier Organic Anion Transporter 1B3; transports conjugated steroids, leukotrienes, prostaglandins.	Steroid metabolism
HCAR2	4673	1.10	9.06E-20	3361	1.22	1.15E-13	5.73E-14	Niacin Receptor 1; receptor for niacin and mediates neutrophil apoptosis and anti-inflammatory effect of butyrate	Anti-inflammatory
PSCA	23905	1.21	9.32E-14	13008	1.87	3.83E-14	6.58E-14	Prostate stem cell antigen; may regulate cell proliferation.	Cell proliferation
TFCP2L1	3228	1.38	2.76E-13	4849	1.40	1.64E-16	1.38E-13	Transcription corepressor activity, and probably Wnt/β-catenin signaling.	Cell proliferation
PRODH	5268	1.20	5.53E-14	4754	1.10	8.22E-13	4.39E-13	Proline Dehydrogenase 1; catalyses proline catabolism.	Cellular metabolism
TSC22D3	7099	1.12	1.19E-17	8967	1.14	1.55E-12	7.73E-13	Glucocorticoid-Induced Leucine Zipper; mediates anti-inflammatory effects of glucocorticoids in macrophages.	Anti-inflammatory
IFITM10	1872	1.55	4.46E-22	1816	1.23	3.71E-11	1.86E-11	IFITM family functions include controlling cell proliferation, and promoting homotypic cell adhesion.	Cell proliferation
ANPEP	2159	1.16	4.30E-14	1707	1.02	6.28E-11	3.14E-11	Aminopeptidase M, CD13; broad specificity aminopeptidase, promotes angiogenesis, and cell growth.	Cell proliferation
KCNB1	602	1.03	1.83E-15	662	1.28	6.63E-10	3.31E-10	Potassium Voltage-Gated Channel Subfamily B Member 1; neurotransmission and regulation of exocytosis.	Cell signalling
GNMT	704	1.28	2.24099E-12	548	1.10	1.97E-07	9.84E-08	Glycine N-Methyltransferase; regulation of methyl group metabolism.	Cellular metabolism

597 **Table 2 – Top upregulated differentially expressed genes**

598 Top 20 upregulated genes common to both epithelial brushes and bronchial biopsies occurring in the top 24 differentially upregulated genes

599 when ranked by FDR p value. Table ranks genes by arithmetic mean of FDR p values across both tissues.

600 **Table 3 – Top downregulated differentially expressed genes**

Gene	Bronchial brushes			Bronchial biopsies			Mean of FDR P values	Comments and aliases	Functional role
	Baseline read count	Log2 fold change	FDR P value	Baseline read count	Log2 fold change	FDR P value			
FCER1A	144	-2.78	2.15E-24	228	-2.25	6.93E-29	1.08E-24	High affinity IgE receptor; expressed on airway mast cells and dendritic cells.	Type 2 immunity
ZNF683	136	-3.33	2.31E-23	131	-3.06	1.32E-20	6.62E-21	Hobit; transcription factor promoting tissue residency in innate and adaptive lymphocytes.	Adaptive immunity
CD207	169	-3.78	3.05E-23	144	-2.90	4.24E-18	2.12E-18	Langerin; C-type lectin with mannose binding specificity, involved in nonclassical antigen-processing.	Antigen presentation
CCL5	1133	-2.39	1.21E-15	1233	-2.15	2.67E-16	7.37E-16	RANTES; chemoattractant for monocytes, memory T helper cells and eosinophils.	Adaptive immunity
IL33	3885	-1.20	2.18E-22	6985	-1.24	3.70E-15	1.85E-15	Interleukin 33; airway epithelial cell alarmin which acts via ST2 to promote type-2 responses.	Alarmin
CD96	253	-1.62	1.31E-12	399	-1.64	3.49E-14	6.71E-13	TACTILE (T cell activation, increased late expression); involved in adhesion of T and NK cells to target cells.	Cell mediated immunity
TARP	100	-2.50	7.30E-15	112	-1.90	3.18E-10	1.59E-10	TCR Gamma Alternate Reading Frame Protein.	T cell adaptive immunity
TRBC1	353	-2.33	3.39E-10	540	-2.07	3.65E-13	1.70E-10	T cell receptor Beta constant chain 1.	T cell adaptive immunity
TRBC2	463	-2.41	7.16E-10	741	-2.07	2.98E-13	3.58E-10	T cell receptor Beta constant chain 2.	T cell adaptive immunity
PTPN22	165	-1.26	1.43E-09	243	-1.52	5.76E-11	7.42E-10	Protein Tyrosine Phosphatase Non-Receptor Type 22. Regulates Treg frequency and T cell motility.	T cell adaptive immunity
TRAC	539	-1.92	3.37E-09	764	-1.84	4.48E-13	1.68E-09	T cell receptor Alpha constant chain.	T cell adaptive immunity
CPA3	228	-2.26	7.00E-09	913	-1.98	1.51E-09	4.26E-09	Carboxypeptidase A3; mast cell-specific peptidase located in secretory granules.	Type 2 immunity
CD2	566	-1.87	1.23E-08	732	-1.87	9.60E-14	6.14E-09	Lymphocyte-Function Antigen-2; T and NK cell marker and co-stimulatory molecule.	T cell adaptive immunity
CLEC10A	135	-1.71	1.82E-08	199	-2.20	4.39E-14	9.11E-09	C-Type Lectin Domain Containing 10A; CD301: marker for alternatively activated macrophages.	Type 2 immunity
SERPINB10	287	-1.18	1.82E-08	350	-1.42	1.25E-12	9.12E-09	Serpin Family B Member 10; inhibits Th2 cell apoptosis, highly upregulated on airway epithelium by IL-13.	Type 2 immunity
CD8A	516	-1.55	6.40E-07	611	-1.52	5.11E-14	3.20E-07	T cell co-receptor for MHC1 restriction.	T cell adaptive immunity
GF11	133	-1.06	1.73E-06	177	-1.23	2.46E-10	8.64E-07	Growth Factor Independent 1 Transcriptional Repressor; involved in haematopoiesis, especially of neutrophils.	Innate immunity
HLA-DQB2	798	-1.01	9.52E-06	640	-1.51	4.63E-18	4.76E-06	Major histocompatibility complex, class II, DQ beta 2	T cell adaptive immunity
CCR5	295	-1.42	9.97E-05	426	-1.91	1.11E-12	4.99E-05	Ligands include CCL5 (RANTES), MCP-2, MIP-1a, MIP-1b. Chemotactic for T2-induced eosinophils.	Type 2 immunity
PTPN7	248	-1.32	0.00033	312	-1.64	2.36E-10	1.67E-04	Protein Tyrosine Phosphatase Non-Receptor 7; regulation of TCR signaling, early response gene in lymphokine stimulated T cell adaptive immunity	T cell adaptive immunity

601

602 Top 20 downregulated genes common to both epithelial brushes and bronchial biopsies occurring in the top 41 biopsy differentially

603 downregulated genes when ranked by FDR p value. Table ranks genes by arithmetic mean of FDR p values across both tissues.

604 **FIGURE LEGENDS**

605 **Figure 1**

606 Immunohistochemical analysis of the lamina propria biopsies showing cell counts and
607 remodelling features on participants with available paired data, before and after 4 weeks
608 treatment with inhaled fluticasone or without treatment. The change in numbers of **A)**
609 eosinophils, with atopic participants shown in red, **B)** tryptase-positive mast cells, **C)** chymase-
610 positive mast cells, or **D)** neutrophils, expressed in absolute counts/mm². Changes in area of
611 **E)** epithelium or **F)** airway smooth muscle (ASM), expressed as a percentage of biopsy area or
612 of **G)** reticular basement membrane (RBM) thickness. Horizontal bars represent mean
613 (SD)(mast cells, neutrophils, ASM, epithelium, RBM) or median (IQR) (eosinophils), analysed
614 by unpaired t test or Mann Whitney U respectively.


615

616 **Figure 2**

617 Changes in gene expression measured by RNAseq in response to 4 weeks treatment with
618 inhaled fluticasone. **A)** Bronchial brush volcano plot. **B)** Bronchial biopsy volcano plot.


619

Figure 1



620

Figure 2



621

622